Loading stock data…
TMDX
$64.30-3.49 (-5.15%)
After Hours$64.42+0.12 (+0.19%)· Last close May 11
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
TransMedics Group, Inc. in the Healthcare sector is trading at $64.30. The stock is currently near its 52-week low of $63.24, remaining 47.2% below its 200-day moving average. Technical signals show oversold RSI of 13 and bearish MACD signal, explaining why TMDX maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 13) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$64.30
Potential Downside
10.7%
Whystock Fair Value$57.44
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Buy
Mean target$117.89+83.3%
Range$85.00 – $142.00
Fundamentals
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a po...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.96B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
23.54
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.08
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.15%
Volume
Today's trading volume
3.16M
Recent News
Assessing TransMedics Group (TMDX) Valuation After A Sharp One Year Share Price Decline
Stock performance context for TransMedics Group investors TransMedics Group (TMDX) has drawn attention after a period of weak share performance, with the stock down about 7% over the past day and about 50% over the past 3 months. That setback contrasts with the company’s current fundamentals, including reported revenue of US$635.89 million and net income of US$171.924 million. These figures give investors concrete financial data to weigh against the recent share price slide. See our latest...
TransMedics Group Inc (TMDX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid ...
TransMedics Group Inc (TMDX) reports a 21% revenue increase while navigating regulatory impacts and competitive pressures.
Glucotrack Submits Blood Glucose Monitoring Technology to FDA
By Daniella Parra Glucotrack, Inc. (Nasdaq: GCTK) said it has submitted an Investigational Device Exemption application to the FDA to begin a U.S. clinical study for its fully implantable continuous blood glucose monitoring technology. The company said it is designed to deliver real-time glucose readings without the need for an external wearable device. “Submission of […]
My Top 3 Stocks to Buy in May
Forget "sell in May and go away." These stocks are good picks to buy and hold.
TMDX Dips After Posting Q1 Earnings & Revenue Miss, Margins Fall
TransMedics' Q1 revenues rise 21% on strong OCS demand, but a sharp EPS miss and margin pressure send shares down despite continued logistics growth.